Literature DB >> 31014059

[Report of breast cancer incidence and mortality in China registry regions, 2008-2012].

M L Zhang1, P Peng1, C X Wu1, Y M Gong1, S W Zhang2, W Q Chen2, P P Bao1.   

Abstract

Objective: The registration data of local cancer registries from 2008 to 2012 were collected by National Central Cancer Registry to estimate the incidence and mortality of female breast cancer in China.
Methods: Data from 135 registries were qualified and selected in the final analysis, and each registry at least has submitted data from 2010 to 2012. Cancer incidence and mortality analyses were stratified by area (urban/rural, eastern/middle/western areas) and age group. The age composition of standard population of Chinese census in 2000 and Segi's population were used for age-standardized incidence and mortality in China and worldwide, respectively.
Results: A total of 135 registries were recruited in the analysis, covering 629 333 910 person-years (382 669 450 in urban and 246 664 460 in rural). About 13, 258 cases of female breast cancer were diagnosed and 32 205 cases were dead between 2008 and 2012. Female breast cancer incidence was 42.67/100, 000 and age-standardized rate calculated by worldwide standard population was 28.87/100, 000. The crude incidence of urban area was 51.85/100, 000, higher than 28.29/100, 000 of rural area, and the crude incidence of eastern area was 46.35/100, 000, higher than 36.38/100, 000 of middle area and 27.60/100, 000 of western area. The age-specific incidence increased with age and reached the peak at age 55-59 (96.36/100, 000), and declined at age 60. The age-standardized incidence rate by Chinese standard population increased 30.56% from 2003 to 2012. The increase rate of rural area was 72.32%, faster than 23.48% of urban area. Female breast cancer mortality was 10.36/100, 000 and the age-standardized rate calculated by worldwide standard population was 6.61/100, 000. The crude mortality of urban area was 11.64/100, 000, higher than 8.36/100, 000 of rural area, and the crude mortality of eastern area was 10.81/100, 000, higher than 7.38/100, 000 of middle area and 9.90/100, 000 of western area. The age-specific incidence increased with age and reached the peak at age above 85 (61.25/100, 000). Age-standardized incidence rate by Chinese standard population remained stable during the period of 2003-2012 (6.23%). The mortality rate mainly increased in rural area (54.94%), while decreased 2.32% in urban area over the 10 years. Conclusions: Although the incidence and mortality of breast cancer in China are comparatively low worldwide, in China the incidence and mortality of female breast cancer have rose to the first and sixth place respectively among all the female cancers. The disease burden of breast cancer is very different between urban and rural area. Therefore, the targeted measure and strategy of control and prevention according to the area difference are needed.

Entities:  

Keywords:  Breast neoplasms; Cancer registry; China; Incidence; Mortality

Mesh:

Year:  2019        PMID: 31014059     DOI: 10.3760/cma.j.issn.0253-3766.2019.04.013

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  7 in total

1.  Circular RNA hsa_circ_0012673 Promotes Breast Cancer Progression via miR-576-3p/SOX4 Axis.

Authors:  Xiangmei Qiu; Qiang Zhang; Qingfang Deng; Quan Li
Journal:  Mol Biotechnol       Date:  2022-07-06       Impact factor: 2.695

2.  LncRNA LINC00665 Promotes Ovarian Cancer Cell Proliferation and Inhibits Apoptosis via Targeting miR-181a-5p/FHDC.

Authors:  Suli Wang; Yingchun Wang; Jin Lu; Jinhua Wang
Journal:  Appl Biochem Biotechnol       Date:  2022-05-07       Impact factor: 3.094

3.  Adherence to post-surgery follow-up assessment and its association with sociodemographic and disease characteristics in patients with breast cancer in Central China.

Authors:  Ran Feng; Jingfeng Jing; Xiaojun Zhang; Ming Li; Jinnan Gao
Journal:  BMC Cancer       Date:  2020-11-12       Impact factor: 4.430

4.  Expression levels and clinical values of miR-92b-3p in breast cancer.

Authors:  Yu Du; Zhuang Miao; Kedi Wang; Yan Lv; Lijuan Qiu; Lusheng Guo
Journal:  World J Surg Oncol       Date:  2021-08-11       Impact factor: 2.754

5.  miR-4324 inhibits ovarian cancer progression by targeting FEN1.

Authors:  Haixia Wu; Youliang Yan; Jialin Yuan; Mengze Luo; Yingjian Wang
Journal:  J Ovarian Res       Date:  2022-03-04       Impact factor: 4.234

6.  Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.

Authors:  Li Peng; Zhen Zhang; Dachun Zhao; Jialin Zhao; Feng Mao; Qiang Sun
Journal:  Pathol Oncol Res       Date:  2021-04-09       Impact factor: 3.201

7.  RP11‑619L19.2 promotes colon cancer development by regulating the miR‑1271‑5p/CD164 axis.

Authors:  Xin-Wu Zhang; Shun-Le Li; Di Zhang; Xiao-Li Sun; Hong-Jun Zhai
Journal:  Oncol Rep       Date:  2020-10-07       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.